ClinicalTrials.gov
public full text
Public Domain
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer#877813
- A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma#850413
- Delirium in extracorporeal membrane oxygenation (ECMO)patients: a systematic review and meta-analysis of prevalence, risk factors, and outcomes / Guangmin Yang ; Jan W. Spillner, Alexander Gombert#1078743
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)#245493
- Ertapenem Administered Subcutaneously Versus Intravenously#417564
Record · ID 837247
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive